At the annual and special meeting of shareholders of the company on Dec. 1, 2023, shareholders approved a special resolution approving the company's share capital consolidation on the basis of one postconsolidation share for 4.1448 preconsolidation shares, as well as a special resolution approving the company's name change. The name of the company has been changed from Cuspis Capital III Ltd. to Cytophage Technologies Ltd.

Effective at the opening Friday, Feb. 9, 2024, the common shares of Cytophage Technologies will commence trading on TSX Venture Exchange, and the common shares of Cuspis Capital III will be delisted.